Your browser doesn't support javascript.
loading
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
Geng, Bob; Hebert, Adelaide A; Takiya, Liza; Miller, Lauren; Werth, John L; Zang, Chuanbo; Sanders, Paul; Lebwohl, Mark G.
Affiliation
  • Geng B; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, UC San Diego School of Medicine, San Diego, CA, USA.
  • Hebert AA; Department of Dermatology, UTHealth McGovern School of Medicine, Houston, TX, USA.
  • Takiya L; Pfizer Inc., Collegeville, PA, USA. liza.takiya@pfizer.com.
  • Miller L; Dermatology Specialists, Gadsden, AL, USA.
  • Werth JL; Pfizer Inc., Collegeville, PA, USA.
  • Zang C; Pfizer Inc., Collegeville, PA, USA.
  • Sanders P; Pfizer R&D UK Ltd., Tadworth, Surrey, UK.
  • Lebwohl MG; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dermatol Ther (Heidelb) ; 11(5): 1679, 2021 Oct.
Article in En | MEDLINE | ID: mdl-34550541
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Dermatol Ther (Heidelb) Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Dermatol Ther (Heidelb) Year: 2021 Type: Article Affiliation country: United States